BioArctic Signs Global Exclusive License Deal with Bristol Myers Squibb for Alzheimer’s Antibody ProgramDecember 19, 20243 Mins Read0 Views BioArctic AB announced a global exclusive license agreement with Bristol Myers Squibb for its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, which includes…
